PMID- 25827643
OWN - NLM
STAT- MEDLINE
DCOM- 20160506
LR  - 20191210
IS  - 1461-7285 (Electronic)
IS  - 0269-8811 (Linking)
VI  - 29
IP  - 8
DP  - 2015 Aug
TI  - Plasma BDNFs level initially and post treatment in acute mania: comparison 
      between ECT and atypical antipsychotic treatment and healthy controls.
PG  - 898-902
LID - 10.1177/0269881115578161 [doi]
AB  - BACKGROUND: Inconsistent findings concerning brain-derived neurotrophic factor 
      (BDNF) levels across different episodes in bipolar disorder have been reported, 
      which is also in line with the treatment effects on BDNF levels in acute mania. 
      We aimed to compare plasma BDNF level alterations after pure antipsychotic drug 
      or ECT plus antipsychotic drug treatment in acute mania. METHODS: Sixty-eight 
      patients with mania were divided into two treatment arms: the antipsychotic 
      treatment arm (AP) and electroconvulsive therapy (ECT)+AP arm. In addition, 30 
      healthy controls were included in the study. RESULTS: There was no significant 
      statistical difference according to mean age, education level, marital and 
      working status between patients and healthy controls. The initial serum BDNF 
      level in patients with acute mania was significantly lower than healthy controls. 
      The initial BDNF level between the ECT arm and AP arm was not significant. The 
      BDNF level decreased significantly after reaching remission in patients with 
      acute mania. The change in BDNF level in the AP arm was not significant while in 
      the ECT arm it was significant after treatment. CONCLUSIONS: In this study, for 
      the first time we revealed a significant decrease in BDNF levels after ECT 
      sessions in acute manic patients. Besides clinical remission after treatment in 
      acute mania, the decrement in BDNF levels does not seem to be related to clinical 
      response. Thus cumulative effects of mood episodes for the ongoing decrease in 
      BDNF levels might be borne in mind despite the achievement of remission and/or 
      more time being required for an increase in BDNF levels after treatment.
CI  - (c) The Author(s) 2015.
FAU - Karamustafalioglu, Nesrin
AU  - Karamustafalioglu N
AD  - Department of Psychiatry, Bakirkoy Mental Health Research and Training State 
      Hospital, Istanbul, Turkey.
FAU - Genc, Abdullah
AU  - Genc A
AD  - Department of Psychiatry, Bakirkoy Mental Health Research and Training State 
      Hospital, Istanbul, Turkey.
FAU - Kalelioglu, Tevfik
AU  - Kalelioglu T
AD  - Department of Psychiatry, Bakirkoy Mental Health Research and Training State 
      Hospital, Istanbul, Turkey.
FAU - Tasdemir, Akif
AU  - Tasdemir A
AD  - Department of Psychiatry, Bakirkoy Mental Health Research and Training State 
      Hospital, Istanbul, Turkey akiftasdemir@mail.com.
FAU - Umut, Gokhan
AU  - Umut G
AD  - Department of Psychiatry, Bakirkoy Mental Health Research and Training State 
      Hospital, Istanbul, Turkey.
FAU - Incir, Said
AU  - Incir S
AD  - Department of Biochemistry, Medical School of Cerrahpasa, Istanbul University, 
      Istanbul, Turkey.
FAU - Akkus, Mustafa
AU  - Akkus M
AD  - Department of Psychiatry, Bakirkoy Mental Health Research and Training State 
      Hospital, Istanbul, Turkey.
FAU - Emul, Murat
AU  - Emul M
AD  - Department of Psychiatry, Medical School of Cerrahpasa, Istanbul University, 
      Istanbul, Turkey.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20150331
PL  - United States
TA  - J Psychopharmacol
JT  - Journal of psychopharmacology (Oxford, England)
JID - 8907828
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 2S3PL1B6UJ (Quetiapine Fumarate)
RN  - 7171WSG8A2 (BDNF protein, human)
RN  - J6292F8L3D (Haloperidol)
SB  - IM
MH  - Adult
MH  - Antipsychotic Agents/administration & dosage/*pharmacology
MH  - Bipolar Disorder/*blood/drug therapy/*therapy
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Electroconvulsive Therapy/*methods
MH  - Female
MH  - Haloperidol/administration & dosage/pharmacology
MH  - Humans
MH  - Male
MH  - *Outcome Assessment, Health Care
MH  - Quetiapine Fumarate/administration & dosage/pharmacology
OTO - NOTNLM
OT  - Brain derived neurotropic factor
OT  - atypical antipsychotics
OT  - electroconvulsive therapy (ECT)
OT  - mania
EDAT- 2015/04/02 06:00
MHDA- 2016/05/07 06:00
CRDT- 2015/04/02 06:00
PHST- 2015/04/02 06:00 [entrez]
PHST- 2015/04/02 06:00 [pubmed]
PHST- 2016/05/07 06:00 [medline]
AID - 0269881115578161 [pii]
AID - 10.1177/0269881115578161 [doi]
PST - ppublish
SO  - J Psychopharmacol. 2015 Aug;29(8):898-902. doi: 10.1177/0269881115578161. Epub 
      2015 Mar 31.